Klin Farmakol Farm. 2007;21(1):22-26

CURRENT TREATMENT OF CYSTIC FIBROSIS

Věra Vávrová1, Jana Bartošová1, MUDr. Libor Fila2,3
1 Pediatrická klinika 2. LF UK a FN Motol, Praha
2 Oddělení TRN, FN Praha Motol
3 Pneumologická klinika 2. LF UK a FN Motol, Praha

Cystic fibrosis is a serious chronic disease, which was first described less than 70 years ago. Since then great progress in understanding the nature of the disease has been made. Patients´ prognosis improved significantly in the mid 1950s, when new antibiotics were introduced. The discovery of chloride transport across the epithelial membrane and especially the discovery of the CFTR gene in 1989 enabled the comprehension of disease aetiology. They also offered the opportunity to search for new therapeutic approaches. The aims of classical symptomatic treatment were to prevent/treat bacterial infection, to improve airway clearance and nutritional status. New methods have now been added; they are focused on better modes of medicament application to the airways, improving airway clearance, fighting inflammation, and searching for, preventing, and treating complications. Great expectations are set on the evolution of new methods targeting the pathophysiology of the disease. Several new medicaments are going through clinical trials. Their aim is to repair the CFTR protein according to the class of mutations, to inhibit the sodium channel and thus to improve the quality of airways surface liquid. Others are focusing on suppressing infection and inflammation. Several of these drugs have received the status of orphan drugs in EU, which enables their quicker development and registration for the indication of cystic fibrosis. Currently new therapeutic approaches only supplement the classical therapy. But they have tremendous promise of potential future benefit in ion transport and in ameliorating or replacing CFTR function.

Keywords: cystic fibrosis, anti-microbial therapy, anti-inflammatory agents, pancreatic substitution, new pharmacological approaches

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vávrová V, Bartošová J, Fila L. CURRENT TREATMENT OF CYSTIC FIBROSIS. Klin Farmakol Farm. 2007;21(1):22-26.
Download citation

References

  1. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080. Go to original source... Go to PubMed...
  2. Riordan JR, Rommens JM, Kerem BS et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073. Go to original source... Go to PubMed...
  3. Rommens JM, Iannuzzi MC, Kerem BS et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065. Go to original source... Go to PubMed...
  4. Vávrová V a kolektiv. Cystická fibróza. Praha: Grada, 2006:516.
  5. Kerem E, Conway S, Elborn S, Heijerman H, Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005;4:7-26. Go to original source... Go to PubMed...
  6. Döring G, Conway SP, Heijerman HG et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767. Go to original source... Go to PubMed...
  7. Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002;1:51-75. Go to original source... Go to PubMed...
  8. Bush A, Alton EWFW, Davies JC, Griesenbach U, Jaffe A, eds. Cystic fibrosis in the 21the century, Progress in respiratory research vol. 34. Basel: Karger, 2006:329. Go to original source...
  9. Holder IA. Pseudomonas immunotherapy: a historical overview. Vaccine 2004;22:831-839. Go to original source... Go to PubMed...
  10. Lang AB, Rudeberg A, Schöni MH, Que JU, Furer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J 2004;23:504-510. Go to original source... Go to PubMed...
  11. Kollberg H, Carlander D, Olesen H, Wejaker PE, Johannesson M, Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 2003;35:433-440. Go to original source... Go to PubMed...
  12. Serisier DJ, Jones G, Carroll M. Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J Cyst Fibros 2004;3:61. Go to original source... Go to PubMed...
  13. Gibson RL, Emerson J, McNamara S et al. Cystic fibrosis therapeutics development network study group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849. Go to original source... Go to PubMed...
  14. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335. Go to original source... Go to PubMed...
  15. Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2006;12:440-444. Go to original source... Go to PubMed...
  16. Mulheran M, Hyman-Taylor P, Tan KH et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 2006;50:2293-2299. Go to original source... Go to PubMed...
  17. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161:1206-1212. Go to original source... Go to PubMed...
  18. Lekkas A, Gyi KM, Hodson ME. Temocillin in the treatment of Burkholderia cepacia infection in cystic fibrosis. J Cyst Fibros 2006;5:121-124. Go to original source... Go to PubMed...
  19. Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 2005;26:305-308. Go to original source... Go to PubMed...
  20. Fila L, Musil J, Vávrová V, Prusík F. Stenotrophomonas maltophilia u nemocných s cystickou fibrózou. Stud Pneumol Phtiseol 2005;65:160-165.
  21. Stevens DA, Moss RB, Kurup VP et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37,Suppl 3:225-264. Go to original source... Go to PubMed...
  22. Prescott WA Jr, Johnson CE. Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 2005;25:555-573. Go to original source... Go to PubMed...
  23. Konstan MW, Krenicky JE, Finney MR et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003;306:1086-1091. Go to original source... Go to PubMed...
  24. Han EE, Beringer PM, Louie SG, Gill MA, Shapiro BJ. Pharmacokinetics of Ibuprofen in children with cystic fibrosis. Clin Pharmacokinet 2004;43:145-156. Go to original source... Go to PubMed...
  25. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2006;350:977-982. Go to original source... Go to PubMed...
  26. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 2006;61:895-902. Go to original source... Go to PubMed...
  27. Paul K, Rietschel E, Ballmann M et al. Bronchoalveolar lavage for the evaluation of antiinflammatory treatment study group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004;169:719-25. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.